YS Biopharma Co., Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of YS Biopharma Co., Ltd. generated cash of -$182,469,396, which is less than the previous year. Cash used in financing activities reached the amount of $317,449,926 last year. Net change in cash is therefore $99,302,322.
Cash Flow
| 2021 | -246.61M | -104.23M | 739.25M |
|---|---|---|---|
| 2022 | -173.54M | -298.92M | 364.55M |
| 2023 | -182.46M | -56.98M | 317.44M |
YS Cash Flow Statement (2021 – 2023)
| 2023 | 2022 | 2021 | |
|---|---|---|---|
Cash at beginning of period | 271.06M | 390.45M | 2.05M |
Operating activities | |||
Net income | -145.47M | -106.00M | -191.82M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 36.68M | 31.15M | 27.90M |
Stock-based compensation expense | 3.50M | 7.76M | 76.75M |
| Deferred income tax benefit | 3.50M | 7.76M | 76.75M |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | -165.24M | -99.13M | -220.73M |
Inventories | -18.15M | -89.45M | -68.72M |
Accounts payable | 49.62M | 14.42M | -4.42M |
Cash generated by operating activities | -182.46M | -173.54M | -246.61M |
Investing activities | |||
Purchases Of Investments | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -57.04M | -298.93M | -104.88M |
Acquisitions Net | 0 | 0 | 0 |
Cash generated by investing activities | -56.98M | -298.92M | -104.23M |
Financing activities | |||
Common Stock Issued | 0 | 0 | 1.58M |
Payments for dividends | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -323.75M |
Cash used in financing activities | 317.44M | 364.55M | 739.25M |
Net Change In Cash | 99.30M | -119.38M | 388.40M |
Cash at end of period | 370.36M | 271.06M | 390.45M |
| Data source |